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Abstract: It has long been recognized that albumin has prognostic value in patients with cancer. 
However, although the Global Leadership Initiative on Malnutrition GLIM criteria (based on five 
diagnostic criteria, three phenotypic criteria and two etiologic criteria) recognize inflammation as 
an important etiologic factor in malnutrition, there are limited data regarding the association 
between albumin, nutritional risk, body composition and systemic inflammation, and whether 
albumin is associated with mortality independent of these parameters. The aim of this study was to 
examine the relationship between albumin, nutritional risk, body composition, systemic 
inflammation, and outcomes in patients with colorectal cancer (CRC). A retrospective cohort study 
(n = 795) was carried out in which patients were divided into normal and hypoalbuminaemic groups 
(albumin  <35 g/L) in the presence and absence of a systemic inflammatory response C-reactive 
protein (CRP >10 and <10 mg/L, respectively). Post-operative complications, severity of 
complications and mortality were considered as outcome measures. Categorical variables were 
analyzed using Chi-square test χ 2or linear-by-linear association. Survival data were analyzed using 
univariate and multivariate Cox regression. In the presence of a systemic inflammatory response, 
hypoalbuminemia was directly associated with Malnutrition Universal Screening Tool MUST (p < 
0.001) and inversely associated with Body Mass Index BMI (p < 0.001), subcutaneous adiposity (p < 
0.01), visceral obesity (p < 0.01), skeletal muscle index (p < 0.001) and skeletal muscle density (p < 
0.001). There was no significant association between hypoalbuminemia and either the presence of 
complications or their severity. In the absence of a systemic inflammatory response (n = 589), 
hypoalbuminemia was directly associated with MUST (p < 0.05) and inversely associated with BMI 
(p < 0.01), subcutaneous adiposity (p < 0.05), visceral adiposity (p < 0.05), skeletal muscle index (p < 
0.01) and skeletal muscle density (p < 0.001). Hypoalbuminemia was, independently of 
inflammatory markers, associated with poorer cancer-specific and overall survival (both p < 0.001). 
The results suggest that hypoalbuminemia in patients with CRC reflects both increased nutritional 
risk and greater systemic inflammatory response and was independently associated with poorer 
survival in patients with CRC. 
Keywords: colorectal cancer; albumin; body composition; nutrition status; systemic inflammatory 
response and colorectal cancer outcomes 
 
Cancers 2020, 12, 1986 2 of 14 
 
1. Introduction 
Albumin is the most abundant plasma protein in humans, representing approximately 50% of 
the total protein content of plasma. Albumin has a myriad of important physiologic functions that 
are essential for normal health. In an adult, the normal range of serum albumin has been defined as 
35–50 g/L and concentrations <35 g/L have been termed hypoalbuminemia [1]. The presence of 
hypoalbuminemia has long been associated with adverse clinical outcomes across a number of 
clinical specialties. For example, in a study of a large number of patients (n = 204,819) undergoing 
surgery, mainly for cancer (56%), Meyer et al. showed that hypoalbuminemia was associated with 
post-operative complications, increased length of hospital stay, and mortality. They recently 
concluded that there was a need to assess preoperative albumin levels and to manage nutritional 
status accordingly [2]. Some have concluded that this is antiquated thinking and ignores the fact that 
albumin is a negative acute phase reactant and that cancer can be considered as an inflammatory 
condition [3,4], and this may in part explain the prognostic value of albumin in patients with cancer. 
Also, serum albumin concentrations do not change in response to short-term changes in nutrient 
intake and in states of malnutrition [5–7]. 
In addition, it is clear that systemic inflammation reduces albumin concentrations independent 
of nutrient intake [5]. Indeed, the reduction in circulating albumin concentrations, as well as an 
increase in C-reactive protein, are linked with poor outcomes in patients with colorectal cancer 
independent of tumor stage and host factors [8–10]. Therefore, despite being addressed repeatedly in 
the literature, there is still a lack of quantitative data regarding the clinical significance of the factors 
that are associated with hypoalbuminemia (including nutritional risk, body composition and 
systemic inflammatory markers). Furthermore, little is known about whether hypoalbuminemia is 
associated with survival independent of these parameters. Through the use of Computerized 
tomography (CT scans), body composition can now be assessed as part of the routine clinical work 
up of patients with cancer, in particular in patients with operable disease [11]. The aim of the present 
study was to examine the relationship between hypoalbuminemia, nutrition-related risk, body 
composition, systemic inflammation and mortality in patients with operable colorectal cancer. 
2. Patients and Methods 
2.1. Patients 
A retrospective cohort study from a prospective database of patients undergoing surgery for 
colorectal cancer (prospectively maintained as part of a surgical audit) was carried out. Consecutive 
patients who underwent potentially curative resection for colorectal cancer between March 2013 and 
June 2016 at Glasgow Royal Infirmary were studied. All patients with recorded routine laboratory 
measurements of white cells, neutrophil, lymphocyte, monocyte and platelet counts, albumin and C-
reactive protein, and who had a preoperative CT scan, were included in the analysis. Patient 
comorbidity was classified using the American Society of Anesthesiologists (ASA) grading system 
[12]. Patients were classified as having anemia based on World Health Organization (WHO) 
guidelines for males (hemoglobin (Hb) < 130 g/L and females; Hb < 120 g/L) [13]. Patients were 
divided into normal and hypoalbuminemic groups according to the widely accepted definition of 
hypoalbuminemia (serum albumin >35/ < 35 g/L) [1]. A subgroup analysis for those patients without 
a systemic inflammatory response (CRP < 10 mg/L; n = 589) has been carried out to examine whether 
there is an independent effect of hypoalbuminemia on MUST and nutritional status based on BMI 
and body composition parameters. Any uncertainties of clinical outcome were addressed by a review 
of electronic and/or the physical case report. 
The study had ethical approval in the UK (West of Scotland Ethics Committee: GN170N474) and 
was conducted in accordance with the Declaration of Helsinki. Furthermore, the study conformed to 
the Strengthening The Reporting of OBservational Studies in Epidemiolog (STROBE) guidelines for 
cohort studies. 
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2.2. Nutritional Risk 
As part of routine clinical practice in the UK, MUST scores were recorded in patient notes within 
24 h of admission. Clinical staff carried out the assessment (usually nursing staff). 
MUST incorporates three components to determine the overall risk for malnutrition: current 
weight status using BMI, unintentional weight loss, and acute disease effect that has induced a phase 
of nil by mouth for > 5 days. Each parameter can be rated as 0, 1, or 2. Overall risk for malnutrition is 
established as low (score = 0), medium (score = 1), or high (score ≥2) [14]. 
2.3. Body Composition 
CT images were obtained at the level of the third lumbar vertebra. Patients whose scans were 
taken 3 months or more prior to their surgery were excluded from the study. The median and range 
for the interval between CT scanning and operation was 0.91 months (0.03–2.83) prior to surgery. 
Scans with significant movement artefact or missing regions of interest were not considered for 
inclusion. Each image was analyzed using ImageJ software [15]. 
Region of interest (ROI) measurements were made of visceral fat (VFA), subcutaneous fat (SFA) 
and skeletal muscle areas (SMA) (cm2) using standard Hounsfield Unit (HU) ranges (adipose tissue 
−190 to −30, and skeletal muscle −29 to +150). These were then normalized for height2 to create indices; 
total fat index (TFI, cm2/m2), subcutaneous fat index (SFI, cm2/m2), visceral fat index (VFI, cm2/m2), 
and skeletal muscle index (SMI, cm2/m2). Skeletal muscle radiodensity (SMD, HU) was measured 
from the same ROI used to calculate SMI, as its mean HU. 
As part of an ongoing research program in the Academic Unit of Surgery, training for body 
composition measurements and analysis was provided. The CT scan analysis was carried out by 
clinical research fellows (AA and RD). The inter-rater reliability was assessed in a sample of 40 patient 
images using interclass correlation coefficients (ICCC) (TFA ICCC = 1.000, SFA ICCC = 1.000, VFA 
ICCC = 1.000, SMA ICCC = 0.998, SMD ICCC = 0.972). 
On the basis of CT-derived body composition, there have been a number of threshold values 
associated with survival in patients with cancer. The thresholds used for SMI and SMD were derived 
from large patient cohorts [16,17]. In particular, SMI is recognized to have prognostic value; the 
threshold used was derived from a large cohort of patients with operable colorectal cancer [16]. 
Visceral obesity was defined as VFA >160 cm2 for male patients and >80 cm2 for female patients 
[18]. High subcutaneous fat index (SFI) was defined as >50.0 cm2 /m2 in males and >42.0 cm2 /m2 in 
females [19]. Sarcopenia was described by Caan and colleagues as SMI < 52.3 cm2/m2 if BMI < 30 kg/m2 
and SMI < 54.3 cm2/m2 if BMI > 30 kg/m2 in male patients and SMI < 38.6 cm2/m2 if BMI < 30 kg/m2 and 
an SMI < 46.6 cm2/m2 if BMI > 30 kg/m2 in female patients [16]. Myosteatosis was defined by SMD < 
41HU in patients with BMI < 25 kg/m2 and <33HU in patients with BMI > 25 kg/m2 [17]. 
2.4. Inflammatory Markers 
Prior to surgery, there was routine clinical assessment of the systemic inflammatory response 
using C-reactive protein, albumin and a differential white cell count. The clinical chemistry 
laboratory at Glasgow Royal Infirmary participated in external quality assurance/proficiency testing 
programs. Performance was acceptable throughout, which indicated that any changes in assay 
methodology did not result in any bias. An autoanalyzer was used to measure serum CRP (mg/L) 
and albumin (g/L) concentrations Grouping of the variables CRP, albumin, white cell, neutrophil, 
lymphocyte, monocyte and platelet counts was carried out using standard thresholds [20–23]. 
2.5. Statistical Analysis 
Statistical analysis was performed using SPSS software, version 24.0 [24]. The data were 
manually extracted from the prospective dataset into SPSS. Categorical variables were analyzed 
using chi-square test χ2 test for linear-by-linear association, or χ2 test for 2-by-2 tables. Missing data 
were excluded from the analysis on a variable by variable basis. 
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Those with mortality within 30 days of the index procedure or during the index admission were 
excluded from subsequent survival analysis. The time between the date of surgery and the date of 
death of any cause was used to define overall survival (OS). The time between the date of surgery 
and the date of death of cancer was used to define cancer specific survival (CS). The rationale for 
including both survival end points was that nutritional biomarkers may impact on both end points. 
Survival data were analyzed using univariate and multivariate Cox regression. Those variables 
associated to a degree of p < 0.1 were entered into a backward conditional multivariate model. Two 
tailed p values <0.001 were considered statistically significant. 
2.6. Results 
A total of 795 patients were included having undergone potentially curative surgery for 
colorectal cancer. The majority were male (55%) and less than 75 years old (74%), had low 
comorbidity (68%), were not anemic (60%), had a MUST score of 0 (79%) and were overweight or 
obese (66%). The majority of patients also had subcutaneous obesity (82%), visceral obesity (73%), 
low SMI (53%) and low SMD (63%) and did not have an elevated systemic inflammatory response as 
evidenced by white cell count (70%), neutrophil count (89%), monocyte count (88%), platelet count 
(88%) and C-reactive protein (75%). 
The relationships between hypoalbuminemia and clinical and pathological characteristics such 
as body composition and host systemic inflammatory response are shown in Table 1. 
Table 1. The relationship between hypoalbuminemia, clinicopathological, CT-derived body 
composition and systemic inflammatory response in 795 patients undergoing surgery for colorectal 
cancer. 
Characteristic 
Total n = 795 
Albumin > 35 g/L  
n = 545 (%) 
Albumin < 35 g/L 




<65 y 221 (41) 64 (25) 
<0.001 65–74 y 225 (41) 79 (32) 
>74 y 99 (18) 107 (43) 
Sex  
Male  302 (55) 138 (55) 
0.955 
Female  243 (45) 112 (45) 
ASAc 
1 113 (25) 46 (18) 
0.004 
2 241 (45) 108 (44) 
3 147 (28) 78 (32) 
4 11 (2) 14 (6) 
TNMd 
0 15 (3) 3 (1) 
0.001 
1 147 (28) 29 (12) 
2 176 (33) 125 (50) 
3 184 (34) 75 (30) 
4 12 (2) 16 (7) 
Nutrition status and body composition 
Hemoglobin  
Normal  389 (72) 82 (33) 
<0.001 
Anemia 155 (28) 165 (67) 
BMI (kg/m2) 
Underweight  22 (4) 16 (7) 
<0.001 
Normal weight 142 (27) 99 (40) 
Overweight  177 (33) 76 (31) 
Obese  191 (36) 54 (22) 
MUST score e  
0 217 (86) 59 (61) 
<0.001 1 13 (5) 18 (19) 
2 23 (9) 20 (21) 
Subcutaneous adiposity 
No 79 (16) 53 (24) 
0.010 
Yes 421 (84) 170 (76) 
Visceral obesity 
No 125 (24) 77 (33) 
0.013 
Yes 397 (76) 159 (67) 
Low SMI f 
No 264 (53) 75 (34) 
<0.001 
Yes 236 (47) 148 (66) 
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Low SMD g 
No 223 (44) 49 (21) 
<0.001 
Yes 288 (56) 183 (79) 
Systemic inflammatory response 
White cell count  
<8.5 × 109-1 406 (75) 153 (62) 
<0.001 8.5–11× 109-1 106 (20) 60 (24) 
>11 × 109-1 31 (6) 34 (14) 
Lymphocyte count 
>3.0 × 109-1 29 (5) 7 (3) 
0.074 1.0–3.0 × 109-1 450 (83) 205 (82) 
<1.0 × 109-1 66 (12) 38 (15) 
Neutrophil count 
<7.5 × 109-1 506 (93) 205 (82) 
<0.001 
>7.5 × 109-1 39 (7) 45 (18) 
Monocyte count 
<0.9 × 109-1 495 (92) 205 (84) 
0.002 
>0.9 × 109-1 46 (8) 39 (16) 
Platelet count  
<400 × 109-1 506 (93) 193 (78) 
<0.001 
>400 × 109-1 36 (7) 54 (22) 
CRP h 
<10 mg/L 461 (85) 128 (51) 
<0.001 
>10 mg/L 79 (15) 121 (49) 
Clinical outcome  
Non-infective complication 
No  447 (83) 191 (78) 
0.068 
Yes 95 (18) 55 (22) 
Infective complication 
No 394 (73) 168 (68) 
0.206 
Yes 148 (27) 78 (32) 
Clavien Dindo grade 
0 337 (62) 142 (58) 
0.309 1–2 154 (28) 80 (32) 
3–5 50 (9) 24 (10) 
5-year survival  
Alive 432 (81) 140 (57) 
<0.001 Cancer-specific death 57 (11) 66 (27) 
Non-cancer death  45 (8) 38 (16) 
a Chi test for linear by linear association; b Significant values in bold p < 0.05; c ASA: American Society 
of Anesthesiologists; d TNM: Tumor–Node–Metastasis; e MUST: Malnutrition Universal Screening 
Tool. Overall risk for malnutrition is established as low (score = 0), medium (score = 1), or high (score 
≥2); f SMI: Skeletal Muscle Index; g SMD: Skeletal Muscle Density; h CRP: C-Reactive Protein. 
In the presence of a systemic inflammatory response (n = 795), hypoalbuminemia was directly 
associated with greater age (p < 0.001), anemia (p < 0.001), comorbidity (p < 0.01), Tumor–Node–
Metastasis TNM (p < 0.001) and MUST (p < 0.001) and inversely associated with BMI (p < 0.001), 
subcutaneous adiposity (p < 0.01), visceral obesity (p < 0.01), skeletal muscle index (p < 0.001) and 
skeletal muscle density (p < 0.001) and all components of a differential white cell count (all p < 0.001) 
except lymphocyte count (p = 0.074). There was no significant association between hypoalbuminemia 
and either the presence of complications or their severity. Hypoalbuminemia was directly associated 
with greater risk of cancer and non-cancer deaths (p < 0.001). 
The relationships between hypoalbuminemia, clinical and pathological characteristics, and body 
composition are shown in Table 2.  
Table 2. The relationship between hypoalbuminemia, clinicopathological, CT-derived body 
composition and systemic inflammatory response in 589 patients with CRP <10 mg/L undergoing 
surgery for colorectal cancer. 
Characteristic 
Total n = 589 
Albumin > 35 g/L 
n= 461(%) 
Albumin < 35 g/L 




<65 y 185 (40) 31 (24) 
<0.001 65–74 y 187 ((41) 42 (33) 
>74 y 89 (19) 55 (43) 
Sex 
Male 256 (55) 70 (55) 
0.865 
Female 205 (45) 58 (45) 
ASAc 
1 118 (26) 30 (24) 
0.094 
2 201 (45) 49 (40) 
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3 124 (27) 39 (31) 
4 8 (2) 7 (6) 
TNM d 
0 14 (3) 2 (2) 
0.024 
1 132 (29) 22 (17) 
2 142 (32) 54 (43) 
3 151 (34) 42 (33) 
4 11 (2) 7 (5) 
Nutrition status and body composition 
Hemoglobin 
Normal 332 (72) 48 (38) 
<0.001 
Anemia 128 (28) 77 (62) 
BMI (kg/m2) 
Underweight 18 (4) 5 (4) 
0.009 
Normal weight 121 (27) 52 (41) 
Over weight 157 (35) 37 (29) 
Obese 154 (34) 32 (25) 
MUST score e 
0: No risk 186 (84) 36 (69) 
0.016 1 and 2: medium and 
high risk 
36 (16) 16 (31) 
Subcutaneous adiposity 
No 64 (15) 28 (25) 
0.016 
Yes 362 (85) 86 (75) 
Visceral obesity 
No 104 (23) 39 (33) 
0.036 
Yes 341 (77) 80 (67) 
Low SMI f 
No 227 (53) 44 (37) 
0.005 
Yes 199 (47) 70 (61) 
Low SMD g 
No 192 (44) 32 (27) 
0.001 
Yes 243 (56) 85 (73) 
Systemic inflammatory response 
White cell count 
<8.5 × 109-1 354 (77) 94 (75) 
0.853 8.5–11× 109-1 86 (19) 27 (22) 
>11 × 109-1 19 (4) 4 (3) 
Lymphocyte count 
>3.0 × 109-1 26 (6) 3 (2) 
0.079 1.0–3.0 × 109-1 378 (82) 104 (81) 
<1.0 × 109-1 57 (12) 21 (16) 
Neutrophil count 
<7.5 × 109-1 434 (94) 116 (91) 
0.157 
>7.5 × 109-1 27 (6) 12 (9) 
Monocyte count 
<0.9 × 109-1 424 (93) 112 (90) 
0.243 
>0.9 × 109-1 33 (7) 13 (10) 
Platelet count 
<400 × 109-1 434 (95) 116 (92) 
0.253 
>400 × 109-1 24 (5) 10 (8) 
Clinical outcome 
Non-infective complication 
No 381 (83) 98 (78) 
0.162 
Yes 77 (17) 28 (22) 
Infective complication 
No 337 (74) 90 (71) 
0.630 
Yes 121 (26) 36 (29) 
Clavien Dindo grade 
0 287 (63) 76 (60) 
0.707 1–2 122 (27) 37 (29) 
3–5 46 (10) 13 (11) 
5-year survival 
Alive 369 (80) 79 (62) 
<0.001 Cancer-specific death 52 (11) 31 (24) 
Non-cancer death 40 (9) 18 (14) 
a Chi test for linear by linear association; b Significant values in bold p < 0.05; c ASA: American Society 
of Anesthesiologists; d TNM: Tumor–Node–Metastasis; e MUST: Malnutrition Universal Screening 
Tool. Overall risk for malnutrition is established as low (score = 0), medium (score = 1), or high (score 
≥2); f SMI: Skeletal Muscle Index; g SMD: Skeletal Muscle Density.In the absence of a systemic 
inflammatory response (C-reactive protein < 10 mg/L, n = 589), hypoalbuminemia was directly 
associated with greater age (p < 0.001), anemia (p < 0.001), TNM (p < 0.05) and MUST (p < 0.05) and 
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inversely associated with BMI (p < 0.01), subcutaneous adiposity (p < 0.05), visceral adiposity (p < 0.05), 
skeletal muscle index (p < 0.01) and skeletal muscle density (p < 0.001), but not components of a 
differential white cell count. There was also no significant association between hypoalbuminemia and 
either the presence of complications or their severity. Hypoalbuminemia was directly associated with 
greater risk of cancer and non-cancer deaths (p < 0.001). 
2.7. Survival 
The relationship between hypoalbuminemia, nutrition status, body composition and cancer-
specific survival in patients undergoing surgery for colorectal cancer is shown in Table 3. 
Table 3. The relationship between hypoalbuminemia, nutritional risk, CT-derived body composition 




HR (95% CI)* 
p-Value 
Multivariate 
HR (95% CI) 
p-Value 
Age (<65/ 65–74/ >74) y 1.35 (1.07–1.70) 0.010 1.05 (0.69–1.62) 0.152 
ASA grade b (1/2/3/4) 1.29 (1.03–1.63) 0.025 1.31 (0.86–1.98) 0.145 
TNM stage (0/1/2/3/4) 2.52 (1.98–3.20) <0.001 3.42 (2.16–5.40) <0.001 
Hypoalbuminemia (no/yes) 2.93 (2.06–4.18) <0.001 1.68 (0.84–3.35) 0.059 
Anemia (no/yes) 1.64 (1.15–2.34) 0.006 1.24 (0.65–2.35) 0.192 
BMI (kg/m2) 
(underweight/normal/overweight/obese) 
0.81 (0.66–0.99) 0.042 0.88 (0.61–1.26) 0.588 
MUST score c (0/1/2) 1.79 (1.27–2.51) 0.001 1.96 (1.38–2.77) <0.001 
Subcutaneous adiposity (no/yes) 0.79 (0.49–1.26) 0.328 - - 
Visceral obesity (no/yes) 0.94 (0.62–1.43) 0.796 - - 
Low SMI d (no/yes) 1.20 (0.82–1.80) 0.326 - - 
Low SMD c (no/yes) 1.38 (0.92–2.07) 0.118 - - 
* HR: Hazard ratio, CI: Confidence Interval. a Variables associated to a degree of p < 0.1 were entered into a backward 
conditional multivariate model. Two-tailed p values <0.001 were considered statistically significant; b ASA: American 
Society of Anesthesiologists; c MUST: Malnutrition Universal Screening Tool. Overall risk for malnutrition is established 
as low (score = 0), medium (score = 1), or high (score ≥2); d SMI: Skeletal Muscle Index; e SMD: Skeletal Muscle Density. 
On univariate analysis, age (p < 0.010), ASA (p < 0.05), TNM stage (p < 0.001), albumin (p < 0.001), 
anemia (p < 0.01), MUST score (p < 0.001) and BMI (p < 0.05) were significantly associated with cancer-
specific survival. On multivariate analysis, TNM stage (HR = 3.42; 95% CI 2.16–5.40, p < 0.001) and 
MUST score (HR = 1.96; 95% CI 1.38–2.77, p = 0.007) were independently associated with cancer-
specific survival. The relationships between hypoalbuminemia, systemic inflammation and cancer-
specific survival in patients undergoing surgery for colorectal cancer is shown in Table 4. 
Table 4. The relationship between hypoalbuminemia, systemic inflammatory response and cancer-




HR (95% CI)* 
p-Value 
Multivariate 
HR (95% CI) 
p-Value 
Age (<65/ 65–74/ >74) y 1.35 (1.07–1.70) 0.010 1.14 (0.89–1.46) 0.164 
ASA grade (1/2/3/4) 1.29 (1.03–1.63) 0.025 1.21 (0.95–1.55) 0.072 
TNM stage (0/1/2/3/4) 2.52 (1.98–3.20) <0.001 2.37 (1.86–3.01) <0.001 
Hypoalbuminemia (no/yes) 2.93 (2.06–4.18) <0.001 2.58 (1.78–3.73) <0.001 
CRP (normal/abnormal) 1.94 (1.34–2.80) <0.001 1.21 (0.79–1.84) 0.442 
White cell count (normal/abnormal) 1.55 (1.21–1.99) <0.001 1.03 (0.71–1.50) 0.719 
Neutrophil count (normal/abnormal) 2.62 (1.69–4.08) <0.001 1.79 (1.11–2.87) 0.016 
Monocyte count (normal/abnormal) 2.36 (1.50–3.73) <0.001 1.67 (1.04–2.70) 0.167 
Platelet count (normal/abnormal) 1.69 (1.05–2.74) 0.030 0.85 (0.48–1.49) 0.944 
* HR: Hazard ratio, CI: Confidence Interval a Variables associated to a degree of p < 0.1 were entered 
into a backward conditional multivariate model. Two-tailed p values <0.001 were considered 
statistically significant. 
On univariate analysis, albumin (p < 0.001) and all inflammatory markers (p < 0.05) were 
significantly associated with overall survival. On multivariate analysis, TNM stage (HR = 2.37; 95% 
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CI 1.86–3.01, p = <0.001), albumin (HR = 2.58; 95% CI 1.78–3.73, p ≤ 0.001) and neutrophil count (HR = 
1.79; 95% CI 1.11–2.87, p = 0.016) were independently associated with cancer-specific survival. 
The relationship between hypoalbuminemia, nutrition status, body composition and overall 
survival in patients undergoing surgery for colorectal cancer is shown in Table 5. 
Table 5. The relationship between hypoalbuminemia, nutritional risk, CT-derived body composition 









Age (<65/ 65–74/ >74) y 1.63 (1.36–1.95) <0.001 1.65 (1.20–2.26) 0.002 
ASA grade b (1/2/3/4) 1.61 (1.35–1.93) <0.001 1.39 (0.99–1.93) 0.093 
TNM stage (0/1/2/3/4) 1.77 (1.48–2.11) <0.001 2.16 (1.56–3.01) <0.001 
Hypoalbuminemia (no/yes) 2.62 (1.99–3.45) <0.001 1.52 (0.87–2.66) 0.112 
Anemia (no/yes) 1.74 (1.32–2.30) <0.001 1.16 (0.69–1.94) 0.290 
BMI (kg/m2) 
(underweight/normal/overweight/obese) 
0.77 (0.66–0.90) 0.001 0.87 (0.65–1.16) 0.627 
MUST score c (0/1/2) 1.63 (1.24–2.14) <0.001 1.53 (1.14–2.05) 0.004 
Subcutaneous adiposity (no/yes) 0.66 (0.47–0.94) 0.021 - - 
Visceral obesity (no/yes) 0.87 (0.63–1.18) 0.377 - - 
Low SMI d (no/yes) 1.6 (1.19–2.23) 0.002 - - 
Low SMD c (no/yes) 1.79 (1.30–2.48) <0.001 1.14 (0.60–2.15) 0.629 
* HR: Hazard ratio, CI: Confidence Interval a Variables associated to a degree of p < 0.1 were entered 
into a backward conditional multivariate model. Two-tailed p values <0.001 were considered 
statistically significant; b ASA: American Society of Anesthesiologists; c MUST: Malnutrition Universal 
Screening Tool. Overall risk for malnutrition is established as low (score = 0), medium (score = 1), or 
high (score ≥2).; d SMI: Skeletal Muscle Index; e SMD: Skeletal Muscle Density. 
On univariate analysis, age (p < 0.00), ASA (p < 0.001), TNM (p < 0.001), albumin (p < 0.001), 
anemia (p < 0.001), BMI (p < 0.001), MUST score (p < 0.001), subcutaneous adiposity (p < 0.050.021), 
SMI (p = 0.002) and SMD (p < 0.001) were significantly associated with overall survival. On 
multivariate analysis, age (HR = 1.65; 95% CI 1.20–2.26, p = 0.002), TNM (HR = 2.16; 95% CI 1.56–3.01, 
p < 0.001) and MUST score (HR = 1.53; 95% CI 1.14–2.05, p = 0.004), were independently associated 
with overall survival. 
The relationship between hypoalbuminemia, systemic inflammation and overall survival in 
patients undergoing surgery for colorectal cancer is shown in Table 6. 
Table 6. The relationship between hypoalbuminemia, systemic inflammation, and overall survival in 




HR (95% CI)* 
p-Value 
Multivariate 
HR (95% CI) 
p-Value 
Age (<65/ 65–74/ >74) y 1.63 (1.36–1.95) <0.001 1.33 (1.09–1.61) 0.004 
ASA grade (1/2/3/4) 1.61 (1.35–1.93) <0.001 1.43 (1.18–1.72) <0.001 
TNM stage (0/1/2/3/4) 1.77 (1.48–2.11) <0.001 1.72 (1.43–2.07) <0.001 
Hypoalbuminemia (no/yes) 2.62 (1.99–3.45) <0.001 1.95 (1.45–2.62) <0.001 
CRP (normal/abnormal) 1.85 (1.39–2.46) <0.001 1.167 (0.83–1.62) 0.318 
White cell count (normal/abnormal) 1.53 (1.26–1.87) <0.001 0.98 (0.73–1.32) 0.897 
Neutrophil count (normal/abnormal) 2.29 (1.60–3.28) <0.001 1.59 (1.08–2.33) 0.017 
Monocyte count (normal/abnormal) 2.19 (1.52–3.14) <0.001 1.57 (1.07–2.29) 0.019 
Platelet count (normal/abnormal) 1.73 (1.19–2.52) 0.004 1.05 (0.69–1.61) 0.628 
* HR: Hazard ratio, CI: Confidence Interval a Variables associated to a degree of p < 0.1 were entered 
into a backward conditional multivariate model. Two-tailed p values <0.001 were considered 
statistically significant. 
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On univariate analysis, albumin (p < 0.001) and all inflammatory markers (p < 0.01) were 
significantly associated with overall survival. On multivariate analysis, age (HR = 1.33; 95% CI 1.09–
1.61, p < 0.01), ASA (HR = 1.43; 95% CI 1.18–1.72, p < 0.001), TNM stage (HR = 1.72; 95% CI 1.43–2.07, 
p < 0.001), albumin (HR = 1.95; 95% CI 1.45–2.62, p < 0.001), neutrophil count (HR = 1.59; 95% CI 1.08-
2.33, p < 0.05) and monocyte count (HR = 1.57, 95% CI 1.07–2.29, p < 0.05) were independently 
associated with overall survival. 
The Kaplan–Meier curves in Figure 1 show the relationship between albumin (normal vs. low) 
and cancer-specific survival (log rank p = 0.001), and Figure 2 shows the relationship between 
albumin (normal vs. low) and overall survival (log rank p = 0.001). 
 
Figure 1. Kaplan–Meier curves showing the relationship between albumin (normal: >35 g/L vs. low: 
<35 g/L) and cancer-specific survival. n = 795. Median follow-up: 38 months. Log rank p = 0.001. 
 
Figure 2. Kaplan–Meier curves showing the relationship between albumin (normal: >35 g/L vs. low: 
<35 g/L) and overall survival. n = 795. Median follow-up: 38 months. Log rank p = 0.001. 
Figure 3 shows the relationship between albumin (normal: >35 g/L vs. low: <35 g/L) and cancer-
specific survival (in the absence of a systemic inflammatory response, CRP < 10 mg/L) (log rank p = 
0.001), and Figure 4 shows the relationship between albumin (normal: >35 g/L vs. low: <35 g/L) and 
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overall survival (in the absence of a systemic inflammatory response, CRP < 10 mg/L) (log rank p = 
0.001). 
 
Figure 3. Kaplan–Meier curves showing the relationship between albumin (normal: >35 g/L vs. low: 
<35 g/L) and cancer-specific survival (in the absence of a systemic inflammatory response, CRP < 10 
mg/L). n = 589. Median follow-up: 38 months. Log rank p = 0.001. 
 
Figure 4. Kaplan–Meier curves showing the relationship between albumin (normal: >35 g/L vs. low: 
<35 g/L) and overall survival (in the absence of a systemic inflammatory response, CRP < 10 mg/L). n 
= 589. Median follow-up: 38 months. Log rank p = 0.001. 
3. Discussion 
The results of the present study show that hypoalbuminemia (<35 g/L) was associated with a 
number of factors including older age, anemia, greater comorbidity and more advanced tumor stage. 
Also, hypoalbuminemia was associated with nutritional risk as evidenced by MUST and body 
composition analysis. Furthermore, hypoalbuminemia was consistently associated with 
measurements of the systemic inflammatory response. Finally, hypoalbuminemia was associated 
with overall survival and cancer-specific survival independent of measurements of the systemic 
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inflammatory response. Therefore, hypoalbuminemia objectively reflects both nutritional and 
inflammatory status and contributes prognostic value to markers of the systemic inflammatory 
response. 
In the present study of patients with operable colorectal cancer, approximately 30% had 
hypoalbuminemia, 25% had evidence of a systemic inflammatory response and 50% had a low SMI 
prior to surgery. Therefore, even in early stage cancer, there is evidence of hypoalbuminemia, 
systemic inflammation and sarcopenia. Whilst the association between albumin and the systemic 
inflammatory response has been shown repeatedly in both acute and chronic inflammation [25,26], 
there is limited data on the association between albumin and body composition. With reference to 
hypoalbuminemia and low SMI, the present results are consistent with two small studies. Low 
muscle mass was associated with lower serum albumin concentration when body composition was 
measured using dual-energy X-ray absorptiometry in the elderly [27]. Similarly, there was an 
association between albumin concentrations and lower lean tissue as measured using a total body 
potassium scanner [28]. 
The basis of the association of hypoalbuminemia and low SMI is not clear. However, it might 
reflect the widespread association between the chronic activation of the systemic inflammatory 
response and catabolic loss of muscle protein in patients with cancer. Indeed, it has been recognized 
that proinflammatory cytokines such as interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis 
factor (TNF) and growth factor (GF), released as part of the systemic inflammatory response, have a 
profound catabolic effect on host tissue metabolism. For example, IL-6 stimulates liver production of 
CRP and other acute phase proteins, thus increasing the demand for amino acids against a 
background of limited intake. In particular, low circulating glutamine concentrations (the most 
abundant amino acid in plasma) have been reported to be associated with hypoalbuminemia, a low 
SMI (major source of glutamine) and poorer survival in patients with colorectal cancer [29–32]. 
Therefore, it would appear the most abundant circulating amino acid (glutamine), circulating protein 
(albumin) and body protein are linked in a chronic systemic inflammatory response and that albumin 
reflects the inter-organ amino acid flux during the chronic systemic inflammatory response. 
The combination of C-reactive protein and albumin, termed the Glasgow Prognostic Score 
(GPS), has been reported to be informative of the nutritional risk of patients with cancer [33] and has 
been used successfully to predict survival in patients with a variety of common solid tumors, both in 
the operable [10] and advanced inoperable setting [9]. Therefore, taken together, the literature points 
to close linkage of nutritional risk and the systemic inflammatory response in patients with cancer 
and indicates that if one is measured, then the other should be measured also [7]. 
There are striking parallels with the work carried out examining micronutrient status in health 
and disease [34,35]. For example, there is now recognition that iron status should be interpreted in 
the context of inflammatory status [36]. Indeed, the combination of C-reactive protein and albumin 
has been used for this purpose. This perhaps points to the fundamental linkage of metabolism and 
inflammation in patients with cancer as there would appear to be an intimate evolutionary link 
between immune and metabolic responses in all mammalian cells, so called immunometabolism [37]. 
The implications of the present observations are important. It has become clear that the systemic 
inflammatory response is an important etiologic factor in the development of cancer cachexia [38,39]. 
However, the presence of albumin is not included in the criteria. Given the present and recent results 
from Silva et al. [33] it is clear that hypoalbuminemia in the presence of a systemic inflammatory 
response offers readily available additional insight into body composition and the likely outcome of 
the patient with operable colorectal cancer. 
The main limitation of the present study was that it was a retrospective study of patients in a 
single institution. In particular, only patients with available CT scans were included in the analysis. 
However, given that a CT scan was part of the routine workup for operable colorectal cancer, less 
than 10% of patients had missing CT scans. In addition, the measurements were taken at one set point 
in time (for colorectal cancer staging) and therefore is a “snapshot” of the patient’s pathway and 
neither the point of onset of nutritional decline or changes in body composition (in particular skeletal 
muscle) are known. Therefore, there may be some selection bias in the present study. However, this 
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study is, to our knowledge, the first to examine the association between a preoperative albumin, a 
nutritional risk tool (MUST), body composition, and systemic inflammation in a large number of 
patients undergoing surgery for primary operable cancer. 
4. Conclusions 
In summary, hypoalbuminemia was associated with greater nutritional risk, anemia, low 
skeletal muscle mass, low skeletal muscle density and the activation of the systemic inflammatory 
response. Moreover, it can provide useful independent prognostic value in patients with colorectal 
cancer. 
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